DEF: Acrivon Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Acrivon Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 13, 2025, featuring the election of Class III directors and ratification of the independent auditor.

Summary

• Acrivon Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 13, 2025.
• Stockholders will vote to elect three Class III directors for a three-year term ending in 2028: Peter Blume-Jensen, Derek DiRocco, and Santhosh Palani.
• The meeting will also include a vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR the election of each director nominee and FOR the ratification of the auditor appointment.
• The record date for determining stockholders eligible to vote is April 21, 2025.
• As of the record date, there were 31,354,984 shares of common stock outstanding and entitled to vote.
• The proxy materials, including the Notice of Annual Meeting, Proxy Statement, and 2024 Annual Report on Form 10-K, are available online at www.proxydocs.com/ACRV.
• Stockholders can vote online, by phone, or by mail prior to the meeting.
• The company encourages stockholders to vote before the Annual Meeting even if they plan to attend.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, outlining the details of the upcoming annual meeting. The tone is professional and forward-looking, with a focus on corporate governance and stockholder engagement. The private placement is a positive sign of investor confidence.

Positives

• The company is utilizing a virtual meeting format to encourage higher stockholder participation and reduce environmental impact.
• The Board of Directors is committed to governance practices tailored to the business and delivering on its commitment to developing precision medicines.
• The company provides multiple methods for stockholders to vote, including online, phone, and mail, to ensure maximum participation.
• The company has a diverse board with members possessing relevant expertise, sound business judgment, and commitment to representing stockholder interests.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company.
• The company's future success depends on its ability to attract, retain, and reward executive officers who contribute to its long-term success.
• The company's compensation policies and practices must be carefully designed to avoid encouraging management to assume excessive risks.

Future Outlook

The Board is committed to guiding Acrivon to deliver on its commitment to developing precision medicines to improve the lives of patients.

Management Comments

• We are pleased to invite you to join us for the 2025 Annual Meeting of Stockholders of Acrivon Therapeutics, Inc., to be held on Friday, June 13, 2025 at 11:00 AM Eastern Time, virtually at during which time you will be able to vote your shares electronically and submit questions.
• Our Board of Directors is committed to governance practices that are appropriately tailored to our business and to guiding Acrivon to deliver on our commitment to developing precision medicines to improve the lives of patients.
• On behalf of the Board of Directors and the Acrivon team, we would like to thank you for your continued support.
• We look forward to your participation at the 2025 Annual Meeting.

Industry Context

The announcement aligns with the trend of biotech companies holding virtual annual meetings to increase accessibility and reduce costs. The focus on electing qualified directors and ratifying auditors is standard practice for publicly traded companies.

Comparison to Industry Standards

• The director compensation policy, including cash retainers and equity awards, is consistent with market practices for newly public biotechnology companies.
• The company's audit committee composition and functions comply with SEC and Nasdaq rules and regulations, aligning with industry standards.
• The company's related person transaction policy is in line with regulatory requirements and best practices for corporate governance.
• The company's executive compensation program, including base salary, annual cash incentives, and equity awards, is designed to attract, retain, and reward executive officers, which is a common practice in the biotechnology industry.
• The company's severance benefits for named executive officers are generally consistent with market practices, providing for cash severance, pro-rata bonus, continuation of health benefits, and accelerated vesting of equity awards upon qualifying terminations.

Management Changes

Corporate Governance

Related Party Transactions

• On June 20, 2024, the Company entered into a written advisory agreement with Dr. Santhosh Palani to provide consulting services to the Company relating to business development, financing and investor relations matters.
• Under the advisory agreement, Dr. Palani is eligible for a $750.00 hourly payment, subject to an annual maximum payment of $120,000.

Stakeholder Impact

• Stockholders are encouraged to participate in the Annual Meeting and vote on the proposals.
• Employees are subject to a code of business conduct and ethics.
• The company's compensation policies are designed to align the interests of executives and stockholders.
• The company's commitment to developing precision medicines aims to improve the lives of patients.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 13, 2025.
• The Audit Committee will continue to oversee the company's accounting and financial reporting processes.
• The Board will continue to monitor and assess strategic risk exposure.
• The company will prepare and file a registration statement with the SEC, covering the resale of the Registrable Securities by no later than May 11, 2024.

Key Dates

Keywords

Annual Meeting, Stockholders, Directors, Proxy Statement, Acrivon Therapeutics, PricewaterhouseCoopers, Audit Committee, Corporate Governance